Skip to contentB
Benitec Biopharma Inc.
B
BNTCBenitec Biopharma Inc. Q3 2023 · 10-Q
Revenue$54.00K$54.00K+12.5% vs Q3 2022 Net Income-$4.40M-$4.40MN/M vs Q3 2022 EPS Diluted-$2.67-$2.67N/M vs Q3 2022 Operating Income-$4,341,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Benitec Biopharma Inc. · CIK 1808898 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-8038.9%−830.6 pt vs Q3 2022
Net margin-8142.6%−1319.7 pt vs Q3 2022
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end